D. Jones

发表

The UK‐PBC risk scores: Derivation and validation of a scoring system for long‐term prediction of end‐stage liver disease in primary biliary cholangitis

S. Sharp, H. Cordell, N. Wareham, 2016, Hepatology.

EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis.

G. Hirschfield, U. Beuers, D. Jones, 2017, Journal of hepatology.

Patient ownership of primary biliary cholangitis long-term management

J. Leighton, D. Jones, J. Dyson, 2020, Frontline Gastroenterology.

The toxicity of the methylimidazolium ionic liquids, with a focus on M8OI and hepatic effects

P. Blain, D. Jones, K. Morse, 2019, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

Identification of a xenobiotic as a potential environmental trigger in primary biliary cholangitis

P. Blain, D. Jones, G. Kass, 2018, Journal of hepatology.

Autotaxin, Bile Acid Profile and Effect of IBAT Inhibition in Primary Biliary Cholangitis Patients with Pruritus

Margaret, Corrigan, Marchesi, 2019 .

HLA class II alleles, genotypes, haplotypes, and amino acids in primary biliary cirrhosis: A large‐scale study

A. Floreani, P. Donaldson, M. Heneghan, 2006, Hepatology.

The Evolving Use of Biochemical Markers in the Management of Primary Biliary Cholangitis: Discussion.

K. Kowdley, G. Hirschfield, D. Jones, 2021, Gastroenterology & hepatology.

A randomized trial of obeticholic acid monotherapy in patients with primary biliary cholangitis

R. Chapman, K. Kowdley, L. Adorini, 2018, Hepatology.

University of Birmingham The British Society of Gastroenterology/UK-PBC Primary Biliary Cholangitis Treatment and Management Guidelines

S. Hübscher, D. Thorburn, Martine Walmsley, 2018 .

A randomized trial of antioxidant therapy alone or with corticosteroids in acute alcoholic hepatitis.

M. Hudson, D. Jones, C. Day, 2007, Journal of hepatology.

The relationship between disease activity and UDCA response criteria in primary biliary cholangitis: A cohort study

R. Sandford, S. Rushbrook, L. Jopson, 2022, EBioMedicine.

The Serum Proteome and Ursodeoxycholic Acid Response in Primary Biliary Cholangitis

R. Sandford, S. Rushbrook, L. Jopson, 2021, Hepatology.

Practical Applications of Biochemistry Results in Primary Biliary Cholangitis.

D. Jones, 2021, Gastroenterology & hepatology.

Letter: histology is relevant for risk stratification in primary biliary cholangitis

G. Mells, G. Hirschfield, M. Carbone, 2020, Alimentary pharmacology & therapeutics.

University of Birmingham Unmet clinical need in autoimmune liver diseases

A. Lohse, G. Hirschfield, U. Beuers, 2014 .

Fat is an immuno‐regulatory issue

David C. Jones, D. Jones, 2005, Hepatology.

EASL Clinical Practice Guidelines: management of cholestatic liver diseases.

F. Lammert, K. Boberg, R. Chapman, 2009, Journal of hepatology.

Metastatic breast carcinoma presenting as acute liver failure and portal hypertension

M. Hudson, D. Jones, K. Agarwal, 2002, American Journal of Gastroenterology.

Clinical Practice Guidelines EASL Clinical Practice Guidelines : The diagnosis and management of patients with primary biliary cholangitis q European Association for the Study of the Liver ⇑

G. Hirschfield, U. Beuers, D. Jones, 2017 .

UDCA prophylaxis for post-transplant PBC recurrence prevention: Time to change practice.

D. Jones, J. Dyson, 2020, Journal of hepatology.

Folic acid handling by the human gut: implications for food fortification and supplementation123

P. Finglas, D. Barrett, M. Hudson, 2014, The American journal of clinical nutrition.

Inequity of care provision and outcome disparity in autoimmune hepatitis in the United Kingdom

A. Lohse, Y. Oo, M. Heneghan, 2018, Alimentary pharmacology & therapeutics.

A trial of antioxidant therapy alone or with corticosteroids in acute alcoholic hepatitis

M. Hudson, D. Jones, C. Day, 2002 .

Single Topic Conference on Autoimmune Liver Disease from the Canadian Association for the Study of the Liver

F. Alvarez, N. Kerkar, A. Montano‐Loza, 2021, Canadian liver journal.

British Association for the Study of the Liver

A. Perelson, C. Dejong, Y. Ma, 1991 .

A phase II, randomized, open-label, 52-week study of seladelpar in patients with primary biliary cholangitis.

P. Thuluvath, C. Mcwherter, C. Berg, 2022, Journal of hepatology.

P399 PBC MANAGEMENT AMONG CLINICIANS: GAPS IN CLINICAL COMPETENCE AND PRACTICE PERFORMANCE – SURVEY FINDINGS

D. Jones, H. Bodenheimer, P. Peterson, 2014 .

Neurosteroid Activation of GABA-A Receptors: A Potential Treatment Target for Symptoms in Primary Biliary Cholangitis?

L. Jopson, G. Mells, D. Jones, 2022, Canadian journal of gastroenterology & hepatology.

Specific considerations for the management of primary biliary cholangitis: are the drug treatment options good enough?

D. Jones, J. Dyson, A. Wetten, 2021, Expert opinion on pharmacotherapy.

Stratified medicine and primary biliary cholangitis.

G. Mells, D. Jones, 2017, The lancet. Gastroenterology & hepatology.

Patient Experience and Characteristics of Cholestatic Pruritus in the UK-PBC Research Cohort

T. Karlsen, R. Sandford, G. Hirschfield, 2014 .

Durability of treatment response after 1 year of therapy with seladelpar in patients with primary biliary cholangitis (PBC): final results of an international phase 2 study

S. Bergheanu, T. Hassanein, B. Bacon, 2020, Journal of Hepatology.

Obeticholic acid therapy improves cognitive decline in cholestatic liver disease

E. Holmes, J. Kirby, D. Jones, 2017 .

LBO-02-Elafibranor, a peroxisome proliferator-activted receptor alpha and delta agonist demonstrates favourable efficacy and safety in patients with primary biliary cholangitis and inadequate response to ursodeoxycholic acid treatment

D. Magrez, K. Kowdley, V. Luketic, 2019, Journal of Hepatology.

Changes in natural killer cells and exhausted memory regulatory T Cells with corticosteroid therapy in acute autoimmune hepatitis

P. Klenerman, J. Hodson, D. Adams, 2018, Hepatology communications.

T‐cell responses to the components of pyruvate dehydrogenase complex in primary biliary cirrhosis

D. Jones, S. Yeaman, M. Bassendine, 1995, Hepatology.

Corrigendum to "The independent effects of fatigue and UDCA therapy on mortality in primary biliary cirrhosis: Results of a 9 year cohort follow-up" J. Hepatol. 2010 Nov; 53(5):911-917.

J. Newton, D. Jones, J. Frith, 2011, Journal of Hepatology.

Falls are common in primary biliary cirrhosis and associate with dysautonomia and distal lower limb weakness

J. Newton, D. Jones, L. Robinson, 2008 .

UK-AIH - Highlighting the need for standardization of treatment in autoimmune hepatitis

D. Jones, J. Dyson, Stuart Kendrick, 2016 .

Substrate promiscuity in the pyruvate dehydrogenase complex (PDC) lipoylation pathway: Xenobiotic incorporation as a potential mechanism for the pathogenesis of primary biliary cirrhosis (PBC)

J. Kirby, D. Jones, Stuart Kendrick, 2007 .

PS-009-Proteome of primary biliary cholangitis in naïve and UDCA treatment patients

G. Mells, D. Jones, Ben Millar, 2019, Journal of Hepatology.

Changing Nomenclature for PBC: From 'Cirrhosis' to 'Cholangitis'.

I. Mackay, R. Gish, David E. J. Jones, 2015, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Changing Nomenclature for PBC: From ‘Cirrhosis' to ‘Cholangitis'

I. Mackay, R. Gish, A. Tanaka, 2015, The American Journal of Gastroenterology.

Pembrolizumab as a Cause of Cholangiopathy in a Patient With Metastatic Melanoma

R. Plummer, D. Jones, N. Cresti, 2019, Hepatology.